In this multicenter , open-label , randomized , superiority trial , adult , febrile , high-risk neutropenic patients ( FhrNPs ) with hematologic malignancies were randomly assigned to receive piperacillin/tazobactam ( @ g intravenously every @ hours ) with or without tigecycline ( @ mg intravenously every @ hours ; loading dose @ mg ) .